• Publications
  • Influence
European Cystic Fibrosis Society Standards of Care: Best Practice guidelines.
Specialised CF care has led to a dramatic improvement in survival in CF: in the last four decades, well above what was seen in the general population over the same period. With the implementation ofExpand
  • 343
  • 18
  • PDF
ECFS best practice guidelines: the 2018 revision.
Developments in managing CF continue to drive dramatic improvements in survival. As newborn screening rolls-out across Europe, CF centres are increasingly caring for cohorts of patients who haveExpand
  • 176
  • 14
  • PDF
European best practice guidelines for cystic fibrosis neonatal screening.
There is wide agreement on the benefits of NBS for CF in terms of lowered disease severity, decreased burden of care, and reduced costs. Risks are mainly associated with disclosure of carrier statusExpand
  • 196
  • 9
  • PDF
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary
Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease, such asExpand
  • 181
  • 6
  • PDF
Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study
Objective To examine compliance with mandatory reporting of summary clinical trial results (within one year of completion of trial) on ClinicalTrials.gov for studies that fall under the recent FoodExpand
  • 253
  • 6
  • PDF
Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis—the TOPIC study: a randomised controlled trial
BACKGROUND Intravenous tobramycin (three-times daily) is widely used for pulmonary exacerbations in patients with cystic fibrosis who have chronic Pseudomonas aeruginosa infection. We undertook aExpand
  • 182
  • 6
  • PDF
Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis.
One hundred and eight patients with cystic fibrosis were investigated over one year to determine whether an association existed between rhinovirus or other respiratory virus infection and clinicalExpand
  • 160
  • 6
  • PDF
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease such asExpand
  • 45
  • 6
  • PDF
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
BACKGROUND Lower respiratory tract infection with Pseudomonas aeruginosa (P. aeruginosa) occurs in most people with cystic fibrosis. Once chronic infection is established, P. aeruginosa is virtuallyExpand
  • 201
  • 5
  • PDF
Oral prednisolone for preschool children with acute virus-induced wheezing.
BACKGROUND Attacks of wheezing induced by upper respiratory viral infections are common in preschool children between the ages of 10 months and 6 years. A short course of oral prednisolone is widelyExpand
  • 279
  • 4
  • PDF